NASDAQ:CRDF Cardiff Oncology Q1 2025 Earnings Results & Report $0.77 -0.03 (-3.71%) Closing price 04:00 PM EasternExtended Trading$0.76 0.00 (-0.30%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cardiff Oncology missed analyst earnings expectations but beat on revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.20 versus the -$0.19 consensus estimate, while revenue of $109 thousand topped the $88 thousand estimate by $21.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call4:00 PM ET Cardiff Oncology EPS ResultsActual EPS-$0.20Consensus EPS -$0.19Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCardiff Oncology Revenue ResultsActual Revenue$109 thousandExpected Revenue$88 thousandBeat/MissBeat by +$21.00 thousandYoY Revenue GrowthN/AUpcoming EarningsCardiff Oncology's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Q1 2025 Earnings FAQ Did Cardiff Oncology beat earnings estimates for Q1 2025? Cardiff Oncology (NASDAQ:CRDF) reported earnings of -$0.20 per share for Q1 2025, missing the consensus estimate of -$0.19. The report was announced on Thursday, May 8, 2025. What was Cardiff Oncology's revenue for Q1 2025? Cardiff Oncology reported revenue of $109 thousand for Q1 2025, against a consensus estimate of $88 thousand. When is Cardiff Oncology's next earnings date? Cardiff Oncology's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cardiff Oncology on the company's earnings history page. Cardiff Oncology Earnings HeadlinesCardiff Oncology to Participate in the UBS Global Biopharma ConferenceNovember 3, 2026 | uk.finance.yahoo.comCardiff Oncology to Participate in the UBS Global Biopharma ConferenceNovember 3, 2026 | globenewswire.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Cardiff Oncology, Inc. Announces Management ChangesOctober 28, 2026 | marketscreener.comMCardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical OfficerOctober 27, 2026 | globenewswire.comCardiff's Onvansertib Wins FDA Orphan Drug Designation For Rare Blood CancerOctober 23, 2026 | rttnews.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division. Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer. Onvansertib is an investigational therapy and has not been approved for commercial use. The company was formerly known as Trovagene, Inc. and adopted the Cardiff Oncology name in 2020 to reflect its focus on oncology drug development. Based in San Diego, California, Cardiff Oncology conducts its research and clinical-development activities primarily through studies in the United States. Mark Erlander has served as the company’s chief executive officer and is a physician-scientist with experience in oncology drug development.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
